Monoclonal antibody COL-1 reacts with restricted epitopes on carcinoembryonic antigen: an immunohistochemical study.

Abstract

We used a monoclonal antibody, MAb COL-1, which recognized a restricted epitope on the carcinoembryonic antigen (CEA) molecule, to stain a wide variety of human normal and cancerous tissues. None of the 35 different types of normal tissue stained with COL-1. Of 59 types of benign and malignant tissues, COL-1 reacted with neoplasms of epithelial origin, especially the gastrointestinal tract, breast, lung, and bladder. In benign adenomatous colon polyps, villous adenomas were more frequently stained than tubular adenomas. Normal colon tissue from individuals without colon disease was unreactive, but very weak reactivity was noted in normal-appearing mucosa several centimeters remote from colon cancers. In contrast, another anti-CEA antibody with a less restricted epitope reacted frequently with both normal and remote colon mucosa. These results indicate that MAb COL-1 recognizes a restricted CEA epitope expressed only on pre-malignant or malignant cells and therefore may be a useful reagent for immunopathology.

Micromachine‐Enabled Capture and Isolation of Cancer Cells in Complex Media

“…Here we demonstrate that these microrockets overcome previous constraints to locomotion in biological fluids and are readily functionalized with an antibody specific for antigenic surface proteins expressed on cancer cells, such as anti-carcinoembryonic antigen (anti-CEA) monoclonal antibody (mAb). [11] CEA is used as a targeting antigen because it is one of the most common antigens among cancer cells, being over-expressed in approximately 95% of colorectal, gastric and pancreatic cancers. [12] Figure 1 conceptually illustrates the microrockets based pick-up and transport of cancer cells.…”

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5 (carcinoembryonic antigen))

“…The CEA expression in those organs starts during the early fetal period (9-14 weeks) and appears to continue throughout one's lifespan (Nap et al, 1988). Increased expression of CEA has also been observed in various cancers including colorectal carcinoma (Jothy et al, 1993), gastric carcinoma (Kinugasa et al, 1998), pancreatic carcinoma (Shi et al, 1994), gall bladder carcinoma (Shi et al, 1994), lung adenocarcinoma (Robbins et al, 1993), small cell lung carcinoma (Kim et al, 1992), breast carcinoma (Cournoyer et al, 1988), urinary bladder carcinoma (Shi et al, 1994), mucinous ovarian carcinoma (Thompson et al, 1994), serous ovarian carcinoma (Thompson et al, 1993) and endometrial adenocarcinoma (Thompson et al, 1993). It is usually expressed in corresponding metastatic lesions as well, due to its involvement in tumor progression and metastasis.…”

A comprehensive overview of radioguided surgery using gamma detection probe technology

“…Those most well studied have included COL-1, A 5 B 7 , IMMU-4, and CL58. COL-1 monoclonal antibody was first derived from reaction with LS-174T human colon carcinoma xenograft in athymic mice, has a very high affinity to CEA, and has been shown to have a high reactivity to significant number of colon, breast, and lung carcinomas [ 30 , 85 , 88 , 89 ]. Likewise, A 5 B 7 , IMMU-4, and CL58 represent three additional anti-CEA murine monoclonal antibodies that have shown clinical relevance by possessing a high reactivity to CEA-producing malignancies [ 30 , 88 , 90 - 93 ].…”